Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19296581 | METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | August 2025 | December 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19069899 | METHODS FOR TREATING NEURODEVELOPMENTAL DISORDERS VIA ADMINISTRATION OF ORGANIC TRICYCLIC COMPOUNDS | March 2025 | July 2025 | Allow | 4 | 1 | 1 | No | No |
| 18996075 | ALCOHOL ETHER COMPOUND AND USE THEREOF IN WATER-BASED NANOPESTICIDE PREPARATION | January 2025 | August 2025 | Allow | 7 | 0 | 1 | Yes | No |
| 19011989 | TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITE | January 2025 | September 2025 | Abandon | 8 | 0 | 1 | No | No |
| 19000200 | KRAS G12D MODULATING COMPOUNDS | December 2024 | May 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18986415 | Method of treating post-traumatic stress disorder with carpipramine | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18941779 | USES OF A CO-CRYSTAL OF PSILOCYBIN AND PSILOCIN | November 2024 | March 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 18915070 | COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | October 2024 | July 2025 | Allow | 10 | 1 | 1 | Yes | No |
| 18885140 | FATTY ACID COMPOSITIONS | September 2024 | April 2025 | Allow | 7 | 2 | 2 | Yes | No |
| 18824610 | TREATMENT OF NEURODEGENERATIVE DISEASE WITH SODIUM CHLORITE | September 2024 | September 2025 | Abandon | 12 | 1 | 0 | No | No |
| 18813944 | METHODS AND COMPOSITIONS INCLUDING PROTOCATECHUIC ACID CRYSTALS FOR THE TREATMENT OF CONDITIONS CAUSED BY AN ENVELOPED VIRUS | August 2024 | July 2025 | Abandon | 11 | 2 | 0 | No | No |
| 18763819 | DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF | July 2024 | December 2025 | Allow | 17 | 3 | 1 | Yes | No |
| 18743944 | Use of Deuterated Empathogens as Therapeutic Agents | June 2024 | September 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18718086 | USE OF FLIBANSERIN IN PREPARATION OF DRUG FOR TREATING ANDROGENIC ALOPECIA | June 2024 | November 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18663502 | QUATERNARY TRYPTAMINES AND THEIR THERAPEUTIC USES | May 2024 | February 2026 | Allow | 21 | 1 | 1 | Yes | No |
| 18654424 | MONOACYLGLYCEROL LIPASE MODULATORS FOR USE IN AUTISM SPECTRUM DISORDERS | May 2024 | August 2025 | Allow | 16 | 0 | 0 | Yes | No |
| 18652039 | GHB DOSING | May 2024 | October 2025 | Abandon | 17 | 2 | 0 | Yes | No |
| 18631828 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD | April 2024 | June 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18429350 | 7-BENZYL-4-(METHYLBENZYL)-2,4,6,7,8,9-HEXAHYDROIMIDAZ0[1,2-A]PYRID0[3,4-E] PYRIMIDIN-5 (1 H)-ONE, SALTS THEREOF AND METHODS OF USING THE SAME IN COMBINATION THERAPY | January 2024 | July 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18572863 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | December 2023 | February 2026 | Allow | 26 | 0 | 0 | Yes | No |
| 18393247 | METHODS AND COMPOSITIONS FOR IMPROVING SLEEP | December 2023 | August 2025 | Allow | 20 | 0 | 0 | Yes | No |
| 18529383 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS | December 2023 | January 2026 | Abandon | 25 | 2 | 0 | Yes | No |
| 18522440 | METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | November 2023 | June 2025 | Allow | 19 | 0 | 1 | No | No |
| 18389182 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | November 2023 | January 2026 | Abandon | 26 | 2 | 0 | No | No |
| 18384394 | NOVEL DIOXANE DERIVATIVES | October 2023 | February 2026 | Allow | 27 | 0 | 1 | No | No |
| 18495587 | METABOLISM ENHANCING COMPOSITIONS | October 2023 | January 2026 | Allow | 26 | 1 | 1 | No | No |
| 18494382 | C1-SUBSTITUTED ISOPROPYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVES | October 2023 | September 2024 | Allow | 11 | 2 | 1 | Yes | No |
| 18552146 | COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | September 2023 | November 2025 | Abandon | 38 | 0 | 1 | No | No |
| 18548717 | COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING SARCOPENIA, CONTAINING D-RIBO-2-HEXULOSE AS ACTIVE INGREDIENT | September 2023 | December 2025 | Allow | 27 | 0 | 0 | No | No |
| 18241419 | 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-Yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid For Use In Metastatic Or Advanced Breast Cancer Patients | September 2023 | July 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18236734 | Long Term Treatment of HIV-Infection With TMC278 | August 2023 | July 2025 | Abandon | 23 | 1 | 0 | Yes | No |
| 18225992 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | July 2023 | April 2025 | Allow | 20 | 0 | 1 | Yes | No |
| 18222720 | EXTRACTION OF ABSCISIC ACID FROM STRAWBERRIES | July 2023 | November 2024 | Abandon | 16 | 3 | 0 | No | No |
| 18344262 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | June 2023 | February 2026 | Allow | 32 | 2 | 0 | No | No |
| 18341853 | PHARMACEUTICAL COMBINATION COMPRISING PONESIMOD | June 2023 | October 2025 | Allow | 27 | 0 | 0 | Yes | No |
| 18341626 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | June 2023 | May 2025 | Allow | 22 | 0 | 1 | Yes | No |
| 18268753 | SMALL-MOLECULE MODULATORS OF THE ORPHAN NUCLEAR RECEPTOR TLX | June 2023 | October 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18253739 | COMPOSITION FOR ENHANCING INTRA-CELLULAR NITRIC OXIDE GENERATION | May 2023 | January 2026 | Allow | 32 | 0 | 1 | Yes | No |
| 18198060 | COMPOSITIONS AND METHODS OF USE OF PHORBOL ESTERS | May 2023 | January 2026 | Abandon | 32 | 2 | 0 | Yes | No |
| 18302997 | USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS, (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID AND VIGABATRIN IN THE TREATMENT OF DEVELOPMENTAL DISORDERS | April 2023 | December 2024 | Allow | 20 | 0 | 0 | Yes | No |
| 18132722 | SOLID FORMS OF A COT INHIBITOR COMPOUND | April 2023 | August 2025 | Allow | 28 | 0 | 0 | No | No |
| 18178429 | Methods for Treating Systemic Lupus Erythematosus | March 2023 | May 2025 | Abandon | 27 | 0 | 1 | No | No |
| 18173743 | COMPOUNDS FOR PREVENTION AND TREATMENT OF HEMORRHAGE AND VASCULATURE INSTABILITY | February 2023 | November 2025 | Allow | 32 | 0 | 1 | Yes | No |
| 18040015 | METHOD FOR PREPARING 3-HYDROXY-3-METHYLBUTYRIC ACID (HMB) OR SALTS THEREOF | January 2023 | July 2025 | Allow | 30 | 0 | 0 | No | No |
| 18006133 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES | January 2023 | March 2026 | Abandon | 38 | 0 | 1 | No | No |
| 17928032 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS | January 2023 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18015277 | METHOD OF TREATMENT FOR PSILOCYBIN OR PSILOCIN INFUSION | January 2023 | November 2025 | Abandon | 34 | 1 | 1 | No | No |
| 18080299 | IONIZABLE LIPIDS AND COMPOSITIONS AND USES THEREOF | December 2022 | November 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17991154 | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | November 2022 | March 2025 | Allow | 27 | 0 | 1 | Yes | No |
| 17988916 | DIROFILARIA VOLATILE ORGANIC COMPOUND SIGNATURES AND USES THEREOF | November 2022 | April 2025 | Abandon | 29 | 0 | 1 | No | No |
| 17998823 | TREATMENT OF ADJUSTMENT DISORDERS | November 2022 | December 2025 | Abandon | 37 | 0 | 1 | No | No |
| 18052814 | SELENOGALACTOSIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH GALECTIN AND THE USE THEREOF | November 2022 | March 2025 | Abandon | 28 | 0 | 1 | No | No |
| 17997438 | PURINE DERIVATIVES AS SIK-3 INHIBITORS | October 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18046064 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | October 2022 | September 2024 | Allow | 23 | 0 | 1 | Yes | No |
| 17934107 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | September 2022 | May 2025 | Abandon | 32 | 2 | 1 | Yes | No |
| 17945427 | TOPICAL MINOCYCLINE OINTMENT FOR SUPPRESSION OF ALLERGIC SKIN RESPONSES | September 2022 | October 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17822934 | PRECURSOR COMPOUNDS FOR MOLECULAR COATINGS | August 2022 | September 2024 | Allow | 25 | 0 | 0 | Yes | No |
| 17817753 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | August 2022 | October 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17877163 | PYRIMIDINE COMPOUNDS AND USE THEREOF | July 2022 | November 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17871584 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | July 2022 | May 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17869993 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | July 2022 | October 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17788516 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR CHRONIC PROSTATITIS/CHRONIC PELVIC PAIN SYNDROME | June 2022 | December 2025 | Allow | 42 | 0 | 1 | Yes | No |
| 17785970 | 2-[2-({12,12-DIMETHYL-4-OXO-6-PHENYL-3,11-DIOXATRICYCLO[8.4.0.0,2,7]TETRADECA-1,5,7,9-TETRAEN-8-YL}OXY)ACETAMIDO]BENZAMIDE AND DERIVATIVES AS INHIBITOR OF CLOCK:BMAL1 INTERACTION FOR THE TREATMENT OF CIRCADIAN RHYTHM DISEASES AND DISORDERS | June 2022 | October 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17838308 | USE OF ANAMORELIN TO TREAT CANCER-RELATED FATIGUE | June 2022 | February 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17778124 | PEPTIDES, COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING SOX9 | May 2022 | March 2026 | Allow | 46 | 0 | 1 | Yes | No |
| 17746250 | NUTRITIONAL PRODUCT | May 2022 | December 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17734177 | COMPOUND-CONTAINING COMPOSITION | May 2022 | March 2026 | Abandon | 46 | 4 | 0 | No | No |
| 17730470 | USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS | April 2022 | January 2025 | Allow | 33 | 2 | 1 | Yes | No |
| 17769966 | INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS | April 2022 | October 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17721835 | COMBINATIONS OF AGENTS TO TREAT HEMATOLOGICAL MALIGNANCIES | April 2022 | July 2025 | Abandon | 39 | 2 | 1 | No | No |
| 17766391 | COMPOSITION CONTAINING CAROTENOIDS AND USE THEREOF FOR PROTECTING NEURONS AGAINST NEURODEGENERATION | April 2022 | September 2025 | Allow | 41 | 0 | 1 | Yes | No |
| 17700392 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | March 2022 | July 2025 | Abandon | 40 | 2 | 1 | Yes | Yes |
| 17700317 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | March 2022 | February 2025 | Allow | 35 | 3 | 0 | Yes | No |
| 17638264 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF TRAUMATIC BRAIN INJURY | February 2022 | January 2026 | Allow | 47 | 2 | 1 | Yes | No |
| 17634729 | Methods of Treating Psychological and Brain Disorders | February 2022 | November 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17631882 | HUMAN AMINOSTEROL ENT-03 COMPOUNDS, RELATED COMPOSITIONS COMPRISING THE SAME, AND METHODS OF USING THE SAME | January 2022 | July 2025 | Allow | 42 | 0 | 1 | Yes | No |
| 17630763 | ARYL HYDROCARBON RECEPTOR ACTIVATORS | January 2022 | July 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17586206 | METHODS FOR TREATING CORONAVIRUS INFECTION | January 2022 | May 2025 | Abandon | 39 | 3 | 0 | Yes | No |
| 17585415 | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | January 2022 | March 2025 | Allow | 38 | 2 | 1 | No | No |
| 17625604 | METHODS AND COMPOSITIONS FOR UNSILENCING IMPRINTED GENES | January 2022 | March 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17625429 | COMBINATION THERAPY OF GPR119 AGONISTS AND DPP-4 INHIBITORS | January 2022 | February 2026 | Allow | 49 | 2 | 1 | Yes | No |
| 17569887 | ORALLY INHALED AND NASAL BENZODIAZEPINES | January 2022 | May 2025 | Abandon | 40 | 4 | 0 | No | No |
| 17617973 | PROCESSES AND COMPOUNDS FOR THE DECARBOXYLATIVE AMINATION OF REDOX-ACTIVE ESTERS WITH DIAZIRINES | December 2021 | November 2025 | Allow | 47 | 2 | 1 | No | No |
| 17546843 | INHIBITORS OF EZH2 AND METHODS OF USE THEREOF | December 2021 | April 2025 | Abandon | 40 | 3 | 0 | Yes | No |
| 17534795 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | November 2021 | May 2025 | Allow | 41 | 4 | 0 | No | No |
| 17528444 | Antimicrobial Composition | November 2021 | February 2025 | Abandon | 39 | 3 | 0 | Yes | No |
| 17604619 | METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | October 2021 | September 2024 | Allow | 35 | 0 | 1 | Yes | No |
| 17602584 | HMOX1 INDUCERS | October 2021 | March 2026 | Abandon | 53 | 2 | 1 | Yes | No |
| 17488433 | PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | September 2021 | September 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17445463 | TREATMENT OF MIGRAINE | August 2021 | February 2025 | Abandon | 42 | 2 | 1 | Yes | Yes |
| 17330122 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING A CYTOCHROME P450 PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | May 2021 | May 2025 | Abandon | 48 | 6 | 2 | Yes | No |
| 17295351 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | May 2021 | September 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17293124 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | May 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17238909 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA-CD47 INTERACTION | April 2021 | February 2025 | Abandon | 46 | 2 | 1 | Yes | No |
| 17131911 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS | December 2020 | March 2024 | Allow | 39 | 3 | 0 | No | No |
| 17253378 | COMPOSITIONS FOR TREATING AND/OR PREVENTING PROTEIN-AGGREGATION DISEASES | December 2020 | September 2025 | Abandon | 57 | 4 | 1 | Yes | Yes |
| 17075167 | COMPOSITIONS COMPRISING MACROCYCLE DERIVATIVES INCORPORATING BRIDGED MACROCYCLES AND METHODS OF PRODUCING AND USING SAME | October 2020 | August 2024 | Allow | 45 | 2 | 1 | Yes | No |
| 17034578 | COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER | September 2020 | March 2026 | Allow | 60 | 4 | 1 | Yes | No |
| 16970384 | CANCER TREATMENT USING COMBINATION OF NEUTROPHIL MODULATOR WITH MODULATOR OF IMMUNE CHECKPOINT | August 2020 | December 2024 | Abandon | 52 | 2 | 1 | No | No |
| 16926552 | NOVEL METHODS | July 2020 | March 2026 | Allow | 60 | 4 | 1 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHONG, YONG SOO.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 43.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHONG, YONG SOO works in Art Unit 1623 and has examined 165 patent applications in our dataset. With an allowance rate of 92.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 40 months.
Examiner CHONG, YONG SOO's allowance rate of 92.7% places them in the 79% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHONG, YONG SOO receive 2.20 office actions before reaching final disposition. This places the examiner in the 60% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CHONG, YONG SOO is 40 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +4.1% benefit to allowance rate for applications examined by CHONG, YONG SOO. This interview benefit is in the 28% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 22.4% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 113.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 80% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 69.5% of appeals filed. This is in the 56% percentile among all examiners. Of these withdrawals, 51.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 41.5% are granted (fully or in part). This grant rate is in the 33% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 7.3% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.6% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.